 |
|
Medication Development and Testing in Children and AdolescentsCurrent Problems, Future Directions
Benedetto Vitiello, MD;
Peter S. Jensen, MD
From the Child and Adolescent Disorders Research Branch, National Institute of Mental Health, Rockville, Md.
Arch Gen Psychiatry. 1997;54(9):871-876.
Abstract
| |
Progress in pediatric psychopharmacological research has suffered notable delay, especially compared with the achievements in adult psychopharmacology. Although safety and efficacy of the use of many psychotropic agents in children remain largely unproved, their pediatric use has been increasing and their widespread off-label prescribing by practitioners has raised some important concerns. The National Institute of Mental Health, in cooperation with the Food and Drug Administration and leading researchers, has coordinated systematic efforts to identify the major obstacles to research in pediatric psychopharmacology and to propose feasible solutions. In 1995, a conference cosponsored by the National Institute of Mental Health and the Food and Drug Administration gathered more than 100 research experts, family and patient advocates, and representatives of mental health professional associations. Participants met in working groups focused on specific aspects of child research and reached consensus on various recommendations. Each of the various aspects relevant to conducting research in this area (methodological, ethical, legal, regulatory, financial, and family or community context) presents specific challenges, which are herein outlined. Recommendations for possible solutions are presented, some of which are being implemented. Because data about drug safety and efficacy in adults can rarely be extrapolated to children, there is no substitute for pediatric psychopharmacological research. Successful strategies for overcoming the many obstacles with which this research has to contend must enlist the concerted efforts of all the relevant parties (investigators, clinicians, industry, federal agencies, ethicists, families, and community representatives).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Safety of Placebo Controls in Pediatric Hypertension Trials
Smith et al.
Hypertension 2008;51:829-833.
ABSTRACT
| FULL TEXT
National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth
Moreno et al.
Arch Gen Psychiatry 2007;64:1032-1039.
ABSTRACT
| FULL TEXT
Stimulating: Prescribing Amidst Controversy
Martin
Am. J. Psychiatry 2006;163:574-577.
FULL TEXT
Prevalence of Atypical Antipsychotic Drug Use Among Commercially Insured Youths in the United States
Curtis et al.
Arch Pediatr Adolesc Med 2005;159:362-366.
ABSTRACT
| FULL TEXT
Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults
Greenhill et al.
Focus 2004;2:642-668.
ABSTRACT
| FULL TEXT
Concomitant Psychotropic Medication for Youths
Safer et al.
Am. J. Psychiatry 2003;160:438-449.
ABSTRACT
| FULL TEXT
Psychopharmacology for Young Children: Clinical Needs and Research Opportunities
Vitiello
Pediatrics 2001;108:983-989.
ABSTRACT
| FULL TEXT
Pediatric Stimulant and Selective Serotonin Reuptake Inhibitor Prescription Trends: 1992 to 1998
Rushton and Whitmire
Arch Pediatr Adolesc Med 2001;155:560-565.
ABSTRACT
| FULL TEXT
Surgeon General's Conference on Children's Mental Health: Developing a National Action Agenda
Scahill
J Am Psychiatr Nurses Assoc 2001;7:51-56.
Off-label prescribing by psychiatrists
Lowe-Ponsford and Baldwin
Psychiatr. Bull. 2000;24:415-417.
ABSTRACT
| FULL TEXT
Pediatrician and Family Physician Prescription of Selective Serotonin Reuptake Inhibitors
Rushton et al.
Pediatrics 2000;105:82e-82.
ABSTRACT
| FULL TEXT
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito et al.
JAMA 2000;283:1025-1030.
ABSTRACT
| FULL TEXT
Child Psychiatric Disorder: Measures, Causal Mechanisms, and Interventions
Rutter
Arch Gen Psychiatry 1997;54:785-789.
ABSTRACT
|
